Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Disease Type
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Autoimmune Disorders
4.1.1.2. Favorable Reimbursement Coverage
4.1.1.3. XX
4.1.2. Restraints:
4.1.2.1. Adverse Effects Associated with the Use of Adalimumab
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
7.3. Market Attractiveness Index, By Disease Type Segment
7.3.1. Rheumatoid Arthritis (RA)*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Psoriatic Arthritis (PsA)
7.3.3. Crohn’s Disease (CD)
7.3.4. Ankylosing Spondylitis (AS)
7.3.5. Plaque Psoriasis (Ps)
7.3.6. Ulcerative Colitis
7.3.7. Others
8. By Distribution Channel
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3. Market Attractiveness Index, By Distribution Channel Segment
8.3.1. Hospitals Pharmacies*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.3.4. Others
9. By Region
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. U.S.
9.4.5.2. Canada
9.4.5.3. Mexico
9.5. Europe
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. Germany
9.5.5.2. U.K.
9.5.5.3. France
9.5.5.4. Italy
9.5.5.5. Spain
9.5.5.6. Rest of Europe
9.6. South America
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.6.5.1. Brazil
9.6.5.2. Argentina
9.6.5.3. Rest of South America
9.7. Asia Pacific
9.7.1. Introduction
9.7.2. Key Region-Specific Dynamics
9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.7.5.1. China
9.7.5.2. India
9.7.5.3. Japan
9.7.5.4. Australia
9.7.5.5. Rest of Asia Pacific
9.8. The Middle East and Africa
9.8.1. Introduction
9.8.2. Key Region-Specific Dynamics
9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. AbbVie Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Amgen Inc.
11.3. Boehringer Ingelheim International GmbH
11.4. Bristol-Myers Squibb Company
11.5. Cadila Healthcare Ltd.
11.6. F. Hoffmann-La Roche Ltd.
11.7. Glenmark Pharmaceuticals
11.8. Hetero Healthcare Limited
11.9. Novartis AG
11.10. Pfizer Inc.
11.11. Torrent Pharmaceuticals Ltd.
11.12. Mylan N.V
11.13. Emcure Pharmaceuticals Ltd.
11.14. Cipla Inc.
11.15. Reliance Life Sciences
11.16. Samsung Bioepis Co Ltd.
11.17. Terumo Corp.
11.18. Fujifilm Kyowa Kirin Biologics Co. Ltd.(LIST NOT EXHAUSTIVE)
12. DataM Intelligence
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us